Lauren Hartle
Private Equity Analyst at Prime Impact Fund
Profile
Lauren Hartle is currently an Associate at Prime Impact Fund since 2020.
Previously, she worked as a Development Technician at AlphaVax, Inc. from 2008 to 2009.
Dr. Hartle holds a doctorate degree from Harvard University and an undergraduate degree from the University of North Carolina System, which she received in 2007.
Lauren Hartle active positions
Companies | Position | Start |
---|---|---|
Prime Impact Fund
Prime Impact Fund Investment ManagersFinance Prime Impact Fund (Prime Impact) is a venture capital firm founded in 2018 by Johanna Wolfson and Matthew Nordan. The firm is headquartered in Cambridge, Massachusetts. | Private Equity Analyst | 2020-05-31 |
Former positions of Lauren Hartle
Companies | Position | End |
---|---|---|
AlphaVax, Inc.
AlphaVax, Inc. Pharmaceuticals: MajorHealth Technology AlphaVax, Inc. involves in clinical-stage biopharmaceutical company. It develops vaccine technology bio products. The firm products include Alphavax and pipleline bio products. It focuses on commercial potential of its alphavaccine vector technology in cancer immunotherapy. The company was founded in 1997 and is headquartered in Durham, NC. | Corporate Officer/Principal | 2009-05-31 |
Training of Lauren Hartle
Harvard University | Doctorate Degree |
University of North Carolina System | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 2 |
---|---|
Prime Impact Fund
Prime Impact Fund Investment ManagersFinance Prime Impact Fund (Prime Impact) is a venture capital firm founded in 2018 by Johanna Wolfson and Matthew Nordan. The firm is headquartered in Cambridge, Massachusetts. | Finance |
AlphaVax, Inc.
AlphaVax, Inc. Pharmaceuticals: MajorHealth Technology AlphaVax, Inc. involves in clinical-stage biopharmaceutical company. It develops vaccine technology bio products. The firm products include Alphavax and pipleline bio products. It focuses on commercial potential of its alphavaccine vector technology in cancer immunotherapy. The company was founded in 1997 and is headquartered in Durham, NC. | Health Technology |
- Stock Market
- Insiders
- Lauren Hartle